Hints and tips:
Related Special Reports
...Emma Walmsley, chief executive of AstraZeneca’s British rival GSK, earned £12.7mn in 2023....
...At the pharma industry conference on Tuesday, GSK chief executive Emma Walmsley said medicines like AIO-001 and its array of vaccines offered ways of “keeping people out of hospital” at a time when “governments...
...Under Emma Walmsley, chief executive since 2017, GSK has struggled to deliver blockbusters: something that has weighed on the £63bn company’s share price....
...Emma Walmsley, GSK’s chief executive, said the over-60s market is far larger than the maternal market — with about 83mn people in the US, compared to about 1.5mn pregnant women — and that new data means...
...The upgrade to the group’s full-year forecasts comes as chief executive Emma Walmsley seeks to overhaul the business, having spun off its consumer division Haleon, which sells over-the-counter medicines,...
...By this reckoning GSK’s chief executive Emma Walmsley will be feeling pretty frustrated this festive season....
...But while AstraZeneca’s growth story is well established, Emma Walmsley, GSK’s chief executive, is still trying to convince investors that she is delivering a “new chapter of growth” after many years of...
...Emma Walmsley, GSK’s chief executive, said the company had made a “strong start to 2023”, with significant approvals and clinical trial results to come....
...Last month, Emma Walmsley, GSK chief executive, asked prime minister Rishi Sunak to increase industry’s access to anonymised NHS patient data....
...But there has been what GSK boss Emma Walmsley calls an “execution gap”, in terms of the momentum and money behind key initiatives....
...Emma Walmsley, chief executive, said 2022 was a “landmark year” for the company. “We enter 2023 with good momentum, underpinning confidence in our ambitious sales and profit outlooks for 2026.”...
...GlaxoSmithKline chief executive Emma Walmsley said the imminent spin-off of the consumer health division Haleon would untangle the UK drugmaker’s complex “Gordian knot” structure and enable her to tackle...
...This is something that chief executive Emma Walmsley has made efforts to address....
...Last year was a “landmark year” for the company, said Emma Walmsley, chief executive....
...The ASX — which appointed a female chief executive in 2022 — suddenly looks in better shape than the FTSE 100, which only counts one female CEO, GSK’s Emma Walmsley, in its top 20 largest businesses....
...De La Riviere pushed for changes at GSK starting in 2021, questioning if chief executive Emma Walmsley was the right candidate to lead the pharmaceutical company after it spun off its consumer health division...
...The results mark a turning point for the company, which had underperformed rivals, and ease the pressure on chief executive Emma Walmsley, who was under siege from activist investor Elliott Management last...
...“We are again raising our full-year guidance and expect good momentum in 2023, further strengthening our confidence in our performance outlooks,” said chief executive Emma Walmsley....
...Emma Walmsley, GSK’s chief executive, has raised R&D spending and appointed a new head....
...Chief executive Emma Walmsley has been looking for the right prescription for investors after sustained underperformance....
...Emma Walmsley, GSK chief executive, said the company was strengthening its pipeline of future drugs, pointing to a recent positive trial result for its vaccine candidate for the respiratory syncytial virus...
...Emma Walmsley, GSK’s chief executive, said the company was strengthening its pipeline of future drugs, pointing to a recent positive trial result for its vaccine candidate for the respiratory syncytial virus...
...The split has been a test for GSK’s Emma Walmsley, chief executive since 2017, who argued it would tackle “perennial underperformance” by leaving the drug company with a stronger balance sheet while setting...
...Chief executive Emma Walmsley said the new FTSE 20 company would build value over time, benefiting shareholders, patients and the UK....
...Emma Walmsley, GSK chief executive, told the Financial Times in July that she believed having more companies selling RSV vaccines would generate more demand....
International Edition